Related Experiment Video
Updated: Jun 5, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Small interfering RNA for effective cancer therapies
1Laboratory of Chemical Biology, Division of Biological Inorganic Chemistry, State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, China.
Abstract:
Small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes, and has turned into a promising tool in molecular medicine. It can be targeted against cancer by several strategies. These include the suppression of overexpressed oncogenes, retarding cell division by interfering with cyclins and related genes or enhancing apoptosis by inhibiting anti-apoptotic genes. RNA interference (RNAi) against multidrug resistance (MDR) genes or chemo/radio-resistance and angiogenesis targets may also provide beneficial cancer treatments. Successful cancer therapy by siRNA in vitro and in vivo provides the enthusiasm for potential therapeutic applications of this technique. Here, we review RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use.
Insights
Small interfering RNA (siRNA) offers a promising approach for cancer therapy by targeting specific genes. While effective in lab and animal studies, challenges remain before clinical application.
Area of Science:
- Molecular Medicine
- Genetics
- Oncology
Background:
- Small interfering RNA (siRNA) is a potent tool for gene silencing.
- siRNA demonstrates potential in various cancer treatment strategies.
- RNA interference (RNAi) is being explored for therapeutic applications in oncology.
Purpose of the Study:
- To review the application of RNA interference (RNAi) in cancer therapy.
- To highlight recent advancements in siRNA-based cancer treatment.
- To examine the obstacles hindering the clinical use of siRNA technology.
Main Methods:
- Review of existing literature on RNAi and siRNA in cancer research.
- Analysis of strategies targeting oncogenes, cell division, apoptosis, multidrug resistance, and angiogenesis.
- Evaluation of in vitro and in vivo studies demonstrating siRNA efficacy.
Main Results:
- siRNA can suppress oncogenes, inhibit cell proliferation, and induce apoptosis.
- RNAi strategies can target multidrug resistance and angiogenesis.
- Successful in vitro and in vivo applications show therapeutic potential.
Conclusions:
- siRNA-based RNAi holds significant promise for novel cancer therapies.
- Overcoming current challenges is crucial for the clinical translation of siRNA technology.
- Further research is needed to fully realize the therapeutic potential of RNAi in oncology.
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:30Small interfering RNAs (siRNA)
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:22MicroRNAs